ABVC Closes $3.39M Discounted Convertible Note Deal and Settles Lind Litigation for $625,000
ABVC sits 49% above its 52-week low of $0.707.
Summary
ABVC closed a $3.39 million private placement of 17.5% OID convertible notes with $4.1 million principal, converting at 85% of VWAP, and used part of the proceeds to pay $625,000 to settle the Lind lawsuit and cancel the Lind notes.
Key Events · Financing and Capital Events · ABVC
-
Discounted Convertible Note Placement Closes
On October 30, 2026, the company sold $4,106,060 principal of 17.5% OID senior convertible notes for $3,387,500 gross. The notes mature June 30, 2027, with a one-time three-month extension that adds 5% to principal.
-
Conversion Terms Below Market
Conversion is at 85% of the three-day VWAP with a $0.20 floor, but not before the eight-month anniversary and only with company consent before maturity; 20,530,304 shares are reserved initially.
-
Lind Lawsuit Settled for $625,000
Under the October 26, 2026 settlement, Lind receives $625,000, the Lind notes are cancelled, all liens are released, the 398,000-share Lind Warrant is increased by 20%, and Lind gets a 12-month 10-25% participation right in future financings.
-
Net Cash Roughly $2.5 Million
After the $237,125 placement agent fee (7%), $65,000 of expense reimbursement, and the $625,000 Lind payment, the remainder funds working capital and subsidiaries.
Analysis · ABVC · Life Sciences
The cost of capital here is steep: ABVC raised $3.39 million in cash against $4.1 million of principal — a 17.5% original issue discount — and the notes convert at 85% of a three-day VWAP, so conversion shares are priced below market by design. Roughly $625,000 of the proceeds goes straight out the door to Lind Global Fund II to end a lawsuit filed in February 2026 and clear the old notes and liens, leaving net cash for operations closer to $2.5 million after the $237,125 placement fee and $65,000 of expense reimbursement. With a Q2 10-Q that already flagged going-concern doubt and minimal cash, this buys time rather than solving the balance sheet. The 19.99% Nasdaq exchange cap means the company must win a shareholder vote by June 30, 2027 or the notes go into default, and the six-month ban on other variable-rate deals limits how it can raise money in the interim.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABVC was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28M. The 52-week trading range was $0.71 to $3.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.